Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

In drug development, there are typically a series of preclinical studies that must be
completed with new compounds or regimens before use in humans. A sequence of in vitro …

Highlights•Tuberculosis (TB) is still a global health threat that requires discovery of new
treatment.•Target-based approaches in TB drug discovery failed to deliver drug candidates …

The recent accelerated approval for use in extensively drug-resistant and multidrug-resistant-
tuberculosis (MDR-TB) of two first-in-class TB drugs, bedaquiline and delamanid, has …

Introduction: Target driven drug discovery is a long and arduous task requiring a huge
investment of time, energy and resources. Therefore, it is very important to select targets …

Standardised management of tuberculosis may soon be replaced by individualised,
precision medicine-guided therapies informed with knowledge provided by the field of …

Introduction: Tuberculosis has been and remains arguably the most important infectious
disease of all time. However, when compared to other diseases of similar human impact …

Introduction Despite new approaches in the diagnosis and treatment of tuberculosis (TB), it
continues to be a major health burden. Several immunotherapies that potentiate the immune …

The past year saw incremental progress rather than dramatic breakthroughs in
mycobacterial disease research. Research in nontuberculous mycobacteria published in the …

There are currently 18 drug classes for the treatment of tuberculosis, including those in the
development pipeline. An in silico simulation enabled combing the innumerably large …